Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
New Study: the PCA3 test could be useful to predict the outcome of an initial prostate biopsy
News
- August 31, 2010 - DiagnoCure to host Q3 2010 Earnings conference call and webcast
- August 23, 2010 - DiagnoCure retains the services of JMP Securities LLC
Events
-
October 3 - 7, 2010
American College of Surgeons 96th Annual Clinical Congress
Washington, D.C., USA
